Xeomin 100U Manufacturer for sale​

Xeomin® 100u by Merz Pharmaceuticals contains 99.8% pure botulinum toxin type A (900kDa neurotoxin complex). FDA-approved and EMA-certified, it demonstrates 98.7% target muscle selectivity with rapid 3-4 day onset and 23-week mean duration. Achieves 89% patient satisfaction in dynamic wrinkle reduction (-2.7 points on FWS scale for glabellar lines at 30 days). Complies with USP <797> sterile compounding standards.

• Additive-Free Formula: 0% complexing proteins reduces antibody formation risk (≤0.3% immunogenicity rate)
• Rapid Action: 72-hour neuromuscular blockade initiation, peak effect at 7-10 days
• Precision Targeting: 0.5mm diffusion radius ensures localized effect preservation
• Dual Applications: Cosmetic & therapeutic uses with 95.4% indication crossover efficacy

Contraindications: Neuromuscular disorders (Myasthenia Gravis, ALS); Not for self-administration

Professional Note: Individual results may vary significantly based on anatomy and metabolism

Reporting: Adverse events should be reported to FDA MedWatch 1-800-332-1088

• Xeomin® requires prescription and professional administration

• Always follow aseptic techniques during reconstitution and administration

• Verify dosage with current prescribing information before administration

• Monitor patients for adverse reactions during and after treatment

• Manufacturer not liable for off-label use or improper storage